HLS Therapeutics Inc. (OTCMKTS:HLTRF) Sees Significant Decrease in Short Interest

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 600 shares, a decline of 14.3% from the August 15th total of 700 shares. Based on an average trading volume of 8,600 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HLTRF. Raymond James decreased their price objective on shares of HLS Therapeutics from C$10.00 to C$9.00 in a research report on Friday, July 28th. Stifel Nicolaus decreased their price target on shares of HLS Therapeutics from C$15.00 to C$12.25 in a report on Tuesday.

HLS Therapeutics Stock Performance

OTCMKTS HLTRF remained flat at $3.30 on Tuesday. 1,400 shares of the company’s stock traded hands, compared to its average volume of 9,420. The stock’s fifty day moving average price is $4.07 and its 200-day moving average price is $4.28. HLS Therapeutics has a twelve month low of $3.20 and a twelve month high of $8.74.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.